Online Inquiry
FGF Receptor 2 (IIIb) Antibody
SPA-03912
| Size | Price |
| 25 µg | Online Inquiry |
| 500 µg | Online Inquiry |
| More Options | Online Inquiry |
| Target Information | |
|---|---|
| Target Name | FGF Receptor |
| Gene Abbr. | FGFR2 |
| Gene ID | 2263 |
| Full Name | fibroblast growth factor receptor 2 |
| Alias | BBDS, BEK, BFR-1, CD332, CEK3 |
| Introduction | Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain. Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues. Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling. The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ.FGFR2 has several splicing isoforms, with ligand specificity largely determined by alternative splicing of exons 8 (IIIb) and 9 (IIIc). Alternative splicing is cell type specific, resulting in isoforms showing various tissue distribution and biological activities. Research studies have shown that mutations in the corresponding FGFR2 gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, Pfeiffer Syndrome, Apert Syndrome, and Jackson-Weiss Syndrome. Investigators have also observed mutations and altered expression of FGFR2 in cases of gastric, endometrial, and breast cancer. |
| Product Details | |
|---|---|
| Host | Mouse |
| Clonality | Monoclonal |
| Clone No. | Available upon request. |
| Isotype | IgG1 |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant human FGF R2 isoforms and S. frugiperda insect ovarian cell line Sf 21-derived recombinant human FGF R2 isoforms. |
| Usage | |
|---|---|
| Application | WB |
| Dilutions | Western Blot (1 µg/mL); Neutralization (2-8 µg/mL) |
| MW(KDa) | 92, 145 |
| Reactivity | Human |
| Specificity | Reacts with multiple isoforms of human FGF R2 although it shows a marked preference for human FGF R2 (IIIb) isoforms in some assays as described below. In direct ELISAs, displays a three-fold preference for FGF R2 (IIIb) isoforms over (IIIc) isoforms. Shows approximately 50% cross-reactivity with recombinant mouse (rm) FGF R2 isoforms and no cross-reactivity with any isoforms of recombinant human (rh) FGF R1 or rhFGF R3. In Western Blots, shows approximately 25% cross-reactivity with rhFGF R2 (IIIc) isoforms, 100% cross-reactivity with all isoforms of rmFGF R2 and no cross-reactivity with any isoforms of rhFGF RI, rhFGF R3, or rhFGF R4. Neutralizes the bioactivity of rhFGF R2 (IIIb) isoforms. |
| Storage & Handling | |
|---|---|
| Storage Buffer | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
| Preservative | No Preservative |
| Storage Temp. | 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Handling | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.